Substitution of Doxil in Ovarian Cancer? There Must Be a Better Way

By Brittany | February 28, 2012 | Category: Cancer, Ovarian cancer, Pharmacotherapy
Substitution of Doxil in Ovarian Cancer? There Must Be a Better Way
By Ralph Tarantino, PhD
Pharmaceutical Consultant and Principal, SteriTech Solutions, LLC
Middletown, NJ

The FDA’s most recent response to the anti-cancer drug shortage crisis may be a perfect example of “too little, too late.” What follows will not be a rant about offshore outsourcing or the regulatory climate in general. However, the FDA decision (See FDA’s Press Release regarding shortages of anti-cancer drugs here) to allow Sun Pharma’s version of Doxil (doxorubicin HCl liposome injection) into the United States to replace the approved Ben Venue product may be a dangerous one for patients with ovarian cancer.

[More]


Month List

RecentComments

Comment RSS